Additionally, the off-the-shelf nature of ImmTACs provides a more accessible and cost-effective treatment option compared to the complex and personalized CAR-T therapies.

Source: https://seekingalpha.com/article/4610744-immunocore-unlocking-immune-systems-hidden-potential?source=feed_all_articles

The process involves CAR-T cells - a type of white blood cell - being taken out of the patient's body in a laboratory, then genetically engineering them to target and attack the deadly cancer.

Source: https://www.9news.com.au/national/diffuse-intrinsic-pontine-glioma-deadly-paediatric-brain-cancer-treatment-trial-sydney-childrens-hospital-randwick/d1c7b3de-4358-4a43-815f-ca8757c567f0

Turning to Slide 14, our GPRC5D targeting CAR-T is a potential first-in-class agent in relapse or refractory multiple myeloma.

Source: https://seekingalpha.com/article/4609793-bristol-myers-squibb-company-bmy-presents-2023-virtual-asco-investor-event-conference?source=feed_all_articles